Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial
Identifieur interne : 001530 ( Main/Exploration ); précédent : 001529; suivant : 001531Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial
Auteurs : Yusuke Iwata [Japon] ; Sachiko Irie [Japon] ; Hiroyuki Uchida [Japon, Canada] ; Takefumi Suzuki [Japon] ; Koichiro Watanabe [Japon] ; Satoru Iwashita [Japon] ; Masaru Mimura [Japon]Source :
- Journal of the neurological sciences [ 0022-510X ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Once developed, tardive dyskinesia (TD) is a challenging condition to treat. The recent evidence has indicated that zonisamide, an antiepileptic drug indicated for partial-onset seizures, may also have beneficial effects for ameliorating dyskinesia in Parkinson's disease. However, this finding has not systematically been tested in psychiatric patients with TD associated with antipsychotic treatment. The objective of this study was to examine the efficacy, tolerability, and safety of zonisamide against TD in these patients. In this 4-week open-label study, subjects who suffered TD were given 50-100 mg/day of add-on zonisamide. Severity of TD was evaluated at the baseline and endpoint, using the Abnormal Involuntary Movement Scale (AIMS). Eleven subjects (6 females; mean±SD age, 75.5 ± 4.7 years; schizophrenia [N=6], bipolar affective disorder [N=2], schizoaffective disorder [N=1], mental retardation [N=1], mental retardation with epilepsy [N=1]; 6 were antipsychotic free at baseline) participated in this study. The AIMS total score (mean±SD) was significantly decreased from 24.1±5.5 to 19.5±5.9, with 36.4% of the subjects (N=4) demonstrating 20% or more decrease in the AIMS total score. Treatment with zonisamide was well-tolerated and no participants dropped out prematurely. In conclusion, zonisamide may be safe and effective for the treatment of TD associated with antipsychotic treatment. These preliminary findings need to be further explored by larger well-designed trials.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000213
- to stream PascalFrancis, to step Curation: 000A39
- to stream PascalFrancis, to step Checkpoint: 000169
- to stream Main, to step Merge: 001583
- to stream Main, to step Curation: 001530
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial</title><author><name sortKey="Iwata, Yusuke" sort="Iwata, Yusuke" uniqKey="Iwata Y" first="Yusuke" last="Iwata">Yusuke Iwata</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Irie, Sachiko" sort="Irie, Sachiko" uniqKey="Irie S" first="Sachiko" last="Irie">Sachiko Irie</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, School of Medicine, Kitasato University</s1><s2>Kanagawa</s2><s3>JPN</s3><sZ>2 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa</wicri:noRegion></affiliation></author><author><name sortKey="Uchida, Hiroyuki" sort="Uchida, Hiroyuki" uniqKey="Uchida H" first="Hiroyuki" last="Uchida">Hiroyuki Uchida</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Geriatric Mental Health Program, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Takefumi" sort="Suzuki, Takefumi" uniqKey="Suzuki T" first="Takefumi" last="Suzuki">Takefumi Suzuki</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Psychiatry, Inokashira Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>4 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Watanabe, Koichiro" sort="Watanabe, Koichiro" uniqKey="Watanabe K" first="Koichiro" last="Watanabe">Koichiro Watanabe</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Iwashita, Satoru" sort="Iwashita, Satoru" uniqKey="Iwashita S" first="Satoru" last="Iwashita">Satoru Iwashita</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Mimura, Masaru" sort="Mimura, Masaru" uniqKey="Mimura M" first="Masaru" last="Mimura">Masaru Mimura</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0158837</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0158837 INIST</idno><idno type="RBID">Pascal:12-0158837</idno><idno type="wicri:Area/PascalFrancis/Corpus">000213</idno><idno type="wicri:Area/PascalFrancis/Curation">000A39</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000169</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000169</idno><idno type="wicri:doubleKey">0022-510X:2012:Iwata Y:effects:of:zonisamide</idno><idno type="wicri:Area/Main/Merge">001583</idno><idno type="wicri:Area/Main/Curation">001530</idno><idno type="wicri:Area/Main/Exploration">001530</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial</title><author><name sortKey="Iwata, Yusuke" sort="Iwata, Yusuke" uniqKey="Iwata Y" first="Yusuke" last="Iwata">Yusuke Iwata</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Irie, Sachiko" sort="Irie, Sachiko" uniqKey="Irie S" first="Sachiko" last="Irie">Sachiko Irie</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, School of Medicine, Kitasato University</s1><s2>Kanagawa</s2><s3>JPN</s3><sZ>2 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa</wicri:noRegion></affiliation></author><author><name sortKey="Uchida, Hiroyuki" sort="Uchida, Hiroyuki" uniqKey="Uchida H" first="Hiroyuki" last="Uchida">Hiroyuki Uchida</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Geriatric Mental Health Program, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Takefumi" sort="Suzuki, Takefumi" uniqKey="Suzuki T" first="Takefumi" last="Suzuki">Takefumi Suzuki</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Psychiatry, Inokashira Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>4 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Watanabe, Koichiro" sort="Watanabe, Koichiro" uniqKey="Watanabe K" first="Koichiro" last="Watanabe">Koichiro Watanabe</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Iwashita, Satoru" sort="Iwashita, Satoru" uniqKey="Iwashita S" first="Satoru" last="Iwashita">Satoru Iwashita</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychiatry, Sakuragaoka Memorial Hospital</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Mimura, Masaru" sort="Mimura, Masaru" uniqKey="Mimura M" first="Masaru" last="Mimura">Masaru Mimura</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Keio University School of Medicine</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of the neurological sciences</title><title level="j" type="abbreviated">J. neurol. sci.</title><idno type="ISSN">0022-510X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of the neurological sciences</title><title level="j" type="abbreviated">J. neurol. sci.</title><idno type="ISSN">0022-510X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticonvulsant</term><term>Dyskinesia</term><term>Free radical</term><term>Nervous system diseases</term><term>Parkinsonism</term><term>Treatment</term><term>Zonisamide</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Parkinsonisme</term><term>Pathologie du système nerveux</term><term>Zonisamide</term><term>Anticonvulsivant</term><term>Radical libre</term><term>Traitement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Once developed, tardive dyskinesia (TD) is a challenging condition to treat. The recent evidence has indicated that zonisamide, an antiepileptic drug indicated for partial-onset seizures, may also have beneficial effects for ameliorating dyskinesia in Parkinson's disease. However, this finding has not systematically been tested in psychiatric patients with TD associated with antipsychotic treatment. The objective of this study was to examine the efficacy, tolerability, and safety of zonisamide against TD in these patients. In this 4-week open-label study, subjects who suffered TD were given 50-100 mg/day of add-on zonisamide. Severity of TD was evaluated at the baseline and endpoint, using the Abnormal Involuntary Movement Scale (AIMS). Eleven subjects (6 females; mean±SD age, 75.5 ± 4.7 years; schizophrenia [N=6], bipolar affective disorder [N=2], schizoaffective disorder [N=1], mental retardation [N=1], mental retardation with epilepsy [N=1]; 6 were antipsychotic free at baseline) participated in this study. The AIMS total score (mean±SD) was significantly decreased from 24.1±5.5 to 19.5±5.9, with 36.4% of the subjects (N=4) demonstrating 20% or more decrease in the AIMS total score. Treatment with zonisamide was well-tolerated and no participants dropped out prematurely. In conclusion, zonisamide may be safe and effective for the treatment of TD associated with antipsychotic treatment. These preliminary findings need to be further explored by larger well-designed trials.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Japon</li></country><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Iwata, Yusuke" sort="Iwata, Yusuke" uniqKey="Iwata Y" first="Yusuke" last="Iwata">Yusuke Iwata</name></noRegion><name sortKey="Irie, Sachiko" sort="Irie, Sachiko" uniqKey="Irie S" first="Sachiko" last="Irie">Sachiko Irie</name><name sortKey="Irie, Sachiko" sort="Irie, Sachiko" uniqKey="Irie S" first="Sachiko" last="Irie">Sachiko Irie</name><name sortKey="Iwashita, Satoru" sort="Iwashita, Satoru" uniqKey="Iwashita S" first="Satoru" last="Iwashita">Satoru Iwashita</name><name sortKey="Iwata, Yusuke" sort="Iwata, Yusuke" uniqKey="Iwata Y" first="Yusuke" last="Iwata">Yusuke Iwata</name><name sortKey="Mimura, Masaru" sort="Mimura, Masaru" uniqKey="Mimura M" first="Masaru" last="Mimura">Masaru Mimura</name><name sortKey="Suzuki, Takefumi" sort="Suzuki, Takefumi" uniqKey="Suzuki T" first="Takefumi" last="Suzuki">Takefumi Suzuki</name><name sortKey="Suzuki, Takefumi" sort="Suzuki, Takefumi" uniqKey="Suzuki T" first="Takefumi" last="Suzuki">Takefumi Suzuki</name><name sortKey="Uchida, Hiroyuki" sort="Uchida, Hiroyuki" uniqKey="Uchida H" first="Hiroyuki" last="Uchida">Hiroyuki Uchida</name><name sortKey="Watanabe, Koichiro" sort="Watanabe, Koichiro" uniqKey="Watanabe K" first="Koichiro" last="Watanabe">Koichiro Watanabe</name></country><country name="Canada"><noRegion><name sortKey="Uchida, Hiroyuki" sort="Uchida, Hiroyuki" uniqKey="Uchida H" first="Hiroyuki" last="Uchida">Hiroyuki Uchida</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0158837
|texte= Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial
}}
| This area was generated with Dilib version V0.6.29. |  |